Open AccessNegative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Author(s) -
Federica Morano,
Salvatore Corallo,
Sara Lonardi,
Alessandra Raimondi,
Chiara Cremolini,
Lorenza Rimassa,
Roberto Murialdo,
Alberto Zaniboni,
Andrea SartoreBianchi,
Gianluca Tomasello,
Patrizia Racca,
Matteo Clavarezza,
Vincenzo Adamo,
Federica Perrone,
Annunziata Gloghini,
Elena Tamborini,
Adele Busico,
Antonia Martinetti,
Federica Palermo,
Fotios Loupakis,
Massimo Milione,
Giovanni Fucà,
Maria Di Bartolomeo,
Filippo de Braud,
Filippo Pietrantonio
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01254
Subject(s) - medicine , panitumumab , colorectal cancer , folfox , oncology , fluorouracil , population , oxaliplatin , clinical endpoint , progression free survival , neuroblastoma ras viral oncogene homolog , cancer , kras , chemotherapy , clinical trial , environmental health
We assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations of anti-epidermal growth factor receptor (EGFR) primary resistance (primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies [PRESSING] panel) in patients with RAS / BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who were randomly assigned to panitumumab plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) induction followed by maintenance with panitumumab with or without fluorouracil (FU) plus leucovorin (LV); Valentino trial (ClinicalTrials.gov identifier: NCT02476045).